Back to top
more

McKesson (MCK)

(Delayed Data from NYSE)

$607.51 USD

607.51
2,465,178

+58.20 (10.60%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $604.00 -3.51 (-0.58%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 22% (54 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Abbott (ABT) Reports Favorable Findings From RELIEF Study

by Zacks Equity Research

The latest data from the RELIEF Study suggests a lower rate of hospitalizations from serious diabetes-related events with Abbott's (ABT) FreeStyle Libre system.

3 Reasons to Retain NextGen (NXGN) Stock in Your Portfolio

by Zacks Equity Research

NextGen's (NXGN) strong product portfolio and solid prospects in the RCM space raise optimism about the stock.

Here's Why You Should Bet on ShockWave Medical (SWAV) Stock

by Zacks Equity Research

ShockWave Medical (SWAV) continues to benefit from solid R&D efforts and commitment to clinical studies.

Here's Why You Should Buy McKesson (MCK) Stock Right Now

by Zacks Equity Research

McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.

Medtronic (MDT) Gets FDA's 510(k) Nod for Pediatric ICM

by Zacks Equity Research

This latest approval broadens Medtronic's scope within its Cardiovascular Diagnostics and Services wing within broader Cardiovascular business.

Nalak Das headshot

Bet on These 5 Ultra-Defensive Stocks for the Rest of 2022

by Nalak Das

We have narrowed our search to five low-beta high-yielding defensive stocks that have strong potential for the rest of 2022. These are: NEE, SO, PEP, CTVA and MCK.

Charles River (CRL) Gains From Growing Demand Amid Macro Woes

by Zacks Equity Research

Charles River (CRL) continues to expect that the growth rate will approach 20% in the second half of 2022.

McKesson (MCK) Stock Pares Gains Following Rx Savings Buyout

by Zacks Equity Research

McKesson (MCK) agrees to buy privately-held Rx Savings Solutions in alignment with its strategic plan of creating accessible and affordable treatment options.

Here's Why You Should Retain Stryker (SYK) Stock For Now

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako, and broad product portfolio. However, pricing pressure weighs on it.

Zimmer Biomet (ZBH) to Offer New Shoulder Replacement System

by Zacks Equity Research

Zimmer Biomet (ZBH) gets FDA nod for the Identity Shoulder System to help surgeons perform anatomic, reverse and revision shoulder replacement with precision.

Abiomed (ABMD) Posts Impellas Positive Study Results in Japan

by Zacks Equity Research

Abiomed's (ABMD) latest multi-center, multi-society study of Impella-supported patients is expected to significantly improve patient outcomes.

3 Reasons to Retain PacBio (PACB) Stock in Your Portfolio

by Zacks Equity Research

PacBio's (PACB) strength in its Sequel system raises optimism about the stock.

Should You Invest in the First Trust Consumer Staples AlphaDEX ETF (FXG)?

by Zacks Equity Research

Sector ETF report for FXG

McKesson (MCK) Stock Moves -0.97%: What You Should Know

by Zacks Equity Research

McKesson (MCK) closed the most recent trading day at $345.56, moving -0.97% from the previous trading session.

Here's Why You Should Retain Intuitive Surgical (ISRG) Stock

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to gain traction from the improving adoption of the da Vinci Surgical System. Higher production costs are a woe.

Quest Diagnostics (DGX) to Offer Lab Services for Lee Health

by Zacks Equity Research

Quest Diagnostics (DGX) inked a new agreement to deliver high-quality diagnostics services for a renowned healthcare provider in Southwest Florida.

Here's Why You Should Retain Boston Scientific (BSX) For Now

by Zacks Equity Research

Investors are optimistic about Boston Scientific's (BSX) impressive top-line results and notable acquisitions.

Inari Medical (NARI) Posts Positive Results of FLASH Registry

by Zacks Equity Research

Inari Medical's (NARI) FlowTriever's latest favorable results are expected to significantly improve the treatment of PE.

Neogen (NEOG) Launches Test for Detection of Cashew Allergen

by Zacks Equity Research

Neogen's (NEOG) new quantitative test shows a high level of specificity to very low levels of cashew protein (down to 0.2 ppm).

Exact Sciences (EXAS) Cologuard Business Grows Amid Cost Woes

by Zacks Equity Research

Following the acquisitions of Paradigm and Ashion, Exact Sciences (EXAS) is now offering therapy selection tests for patients with advanced cancer.

The Zacks Analyst Blog Highlights Corteva, Hershey, National Fuel Gas and McKesson

by Zacks Equity Research

Corteva, Hershey, National Fuel Gas and McKesson are included in this Analyst Blog.

Derek Lewis headshot

Defense Wins Ballgames; 3 Blue-Chip Stocks To Consider

by Derek Lewis

Due to their well-established nature and track records of success, these companies are positioned to weather a dark fiscal cloud better than most.

QIAGEN (QGEN) Assays to Detect Organ Transplant-Related Viruses

by Zacks Equity Research

QIAGEN's (QGEN) latest additions to the NeuMoDx assay menu will help identify EBV and HHV-6 viruses in immunocompromised patients.

3 Reasons to Hold QuidelOrtho (QDEL) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its strong product portfolio.

Teleflex (TFX) Witnesses Lower UroLift Sales, Cost Woes

by Zacks Equity Research

Teleflex's (TFX) lowered revenue and adjusted EPS outlook for 2022 indicates lackluster performance, which increases investors' concern.